

Monahan, Meghan E.

From: Monahan, Meghan E.

Sent: Friday, April 10, 2009 9:05 AM

Subject: Clinical Investigations Leadership Committee (CLC) Webpage

Dear DF/HCC Research Community,

The Clinical Investigations Leadership Committee (CLC) is pleased to announce the launch of their recently redesigned webpage. One of the missions of the CLC is to provide guidance for controversial issues faced by clinical investigators at DF/HCC. Recent topics discussed by the CLC include the criteria for evaluating combinations of targeted agents in phase I trials, and the criteria for evaluating randomized phase II trials. Summary reports are now available online. You are invited to view these reports, and we welcome your feedback. It is hoped that the CLC's deliberations will generate discussion within the broad research community at DF/HCC.

The Clinical Investigations Leadership Committee webpage can be found: https://www.dfhcc.harvard.edu/membership/login/?%20return_url=clinical-research-support%2Fclinical-investigations-leadership-committee-clc%2F&pageId=2183

Stephen A. Cannistra, M.D.
Professor of Medicine
Harvard Medical School
Director, Gynecologic Medical Oncology
Beth Israel Deaconess Medical Center
330 Brookline Avenue
Boston, MA 02215
Telephone: 617-667-4283
Fax: 617-975-5598

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error contains patient information, please contact the Partners Compliance HelpLine at <http://www.partners.org/complianceline> . If the e-mail does not contain patient information, please contact the sender and properly dispose of the e-mail.